Designing Products With
Enhanced Tumor Retention & Improved Safety Profile
Immune-modulating therapies hold great promise in treating cancer and other serious immune-mediated diseases, but their clinical efficacy has been limited.
Our anchored immunotherapy platform creates localized therapies that keep powerful immune-modulating drugs at the disease site where they are needed most.
By linking therapeutic molecules to aluminum hydroxide, we anchor the treatment directly at the target site to maximize local drug concentration. This innovative approach successfully broadens the therapeutic window, prolongs local anti-tumor immune activation, prevents systemic side effects from drug leakage, and reduces dosing frequency.
Our First Anchored Immunotherapy
ANK-101
After demonstrating potent therapeutic activity with a single dose in multiple preclinical models, our anchored IL-12 is now being evaluated in patients with advanced solid tumors.
Our Collaborators
Our Investors
